Iloprost

Iloprost. Its chemical name is: 5-(E)-(1S,5S,6R,7R)-7-hydroxy-6-[(E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl]-bicyclo[3.3.0]octan-3-ylidene-pentanoic acid. Molecular weight: C22H32O4

Iloprost can enhance the antihypertensive effect of drugs such as beta-receptor blockers, calcium ion antagonists, vasodilators and angiotensin converting enzyme inhibitors. Because iloprost has the effect of inhibiting platelet function, it can increase the risk of bleeding when used in combination with anticoagulants (such as heparin, coumarin anticoagulants) or other drugs that inhibit platelet aggregation (such as acetylsalicylic acid, nonsteroidal anti-inflammatory drugs, phosphodiesterase inhibitors and nitrovasodilators). The interaction between intravenous infusion of iloprost and digoxin, acetylsalicylic acid and tissue plasminogen activator (t-PA) was studied. The results showed that intravenous infusion of iloprost did not affect the pharmacokinetics of patients after multiple oral digoxin, nor did it affect the pharmacokinetics of t-PA given at the same time. Animal experiments have found that iloprost may lead to a decrease in the steady-state blood concentration of t-PA. Animal experiments have shown that pre-administration of glucocorticoids can reduce the vasodilatory effect of iloprost, but does not affect the inhibitory effect on platelet aggregation. The significance of this finding for the drug's use in humans is unclear.

Iloprost. Its chemical name is: 5-(E)-(1S,5S,6R,7R)-7-hydroxy-6-[(E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl]-bicyclo[3.3.0]octan-3-ylidene-pentanoic acid. Molecular weight: C22H32O4

Iloprost can enhance the antihypertensive effect of drugs such as beta-receptor blockers, calcium ion antagonists, vasodilators and angiotensin converting enzyme inhibitors. Because iloprost has the effect of inhibiting platelet function, it can increase the risk of bleeding when used in combination with anticoagulants (such as heparin, coumarin anticoagulants) or other drugs that inhibit platelet aggregation (such as acetylsalicylic acid, nonsteroidal anti-inflammatory drugs, phosphodiesterase inhibitors and nitrovasodilators). The interaction between intravenous infusion of iloprost and digoxin, acetylsalicylic acid and tissue plasminogen activator (t-PA) was studied. The results showed that intravenous infusion of iloprost did not affect the pharmacokinetics of patients after multiple oral digoxin, nor did it affect the pharmacokinetics of t-PA given at the same time. Animal experiments have found that iloprost may lead to a decrease in the steady-state blood concentration of t-PA. Animal experiments have shown that pre-administration of glucocorticoids can reduce the vasodilatory effect of iloprost, but does not affect the inhibitory effect on platelet aggregation. The significance of this finding for the drug's use in humans is unclear.